Inflammation is an important determinant of the severity and outcome of central nervous system injury. The endogenous antiinflammatory cytokine interleukin-10 (IL-10) is upregulated in the injured adult central nervous system where it controls and terminates inflammatory processes. The developing brain, however, displays differences in susceptibility to insults and in associated inflammatory responses from the adult brain; the anatomic and temporal patterns of injury-induced IL-10 expression in the immature brain after excitotoxic injury are unknown. We analyzed the spaciotemporal gene and protein expression of IL-10 and its receptor (IL-10RI) in N-methyl-DaspartateYinduced excitotoxic injury in 9-day-old and control rats using quantitative reverse transcriptase polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry. In noninjected control brains, both molecules were expressed mainly in white matter on glial cells and blood vessels; IL-10 was also observed on blood vessels in gray matter and in glial fibrillary acidic protein-positive processes in the hippocampus and near leptomeningeal and ventricle surfaces. In N-methyl-D-aspartateYinjected brains, IL-10 gene and protein expression were maximal at 72 hours postinjection; IL-10RI gene and protein expression peaked at 48 hours postinjection. Interleukin-10 and IL-10RI expression in injured areas was mainly found in reactive astrocytes and in microglia/macrophages. The expression patterns of IL-10 and IL-10R suggest possible developmental roles, and their upregulation after injury suggests that this expression may have anti-inflammatory effects in distinct anatomic sites in the immature brain.
INTRODUCTION
The central nervous system (CNS) inflammatory response is characterized by a variety of complex and interrelated events, including cellular responses such as increased astroglial and microglial reactivity and leukocyte infiltration; these responses are tightly regulated by cytokines, chemokines, adhesion molecules, and growth factors in an intricate signaling circuitry. Because inflammation is a major determinant of injury initiation, progression, and lesion outcome, many studies have been directed toward understanding the effects exerted by proinflammatory and anti-inflammatory cytokines in CNS injury (1Y3).
Among the anti-inflammatory cytokines, interleukin-10 (IL-10) is a homodimeric protein with a molecular mass of 37 kDa that acts through the activation of its receptor (IL-10R). Upon ligand binding, the receptor oligomerizes into a tetramer composed of 2 ligand-binding subunits (IL-10RI) and 2 accessory subunits (IL-10RII) that in turn activate an intracellular signaling cascade (4) . In recent years, IL-10 has been implicated as playing a crucial role in the control and termination of CNS inflammation (3) . Specifically, IL-10 expression has been reported to be upregulated in CNS inflammatory conditions such as multiple sclerosis (MS) (5) and the MS model experimental autoimmune encephalomyelitis (6, 7) , middle cerebral artery occlusion (8) , traumatic brain injury (9) , and in a genetic model of A-amyloid accumulation (10) . It is noteworthy that the upregulation of IL-10 expression after middle cerebral artery occlusion correlates temporally with decreased expression of proinflammatory molecules (8) and that the lack of IL-10 in knockout mice results in elevated production of proinflammatory cytokines after endotoxic shock (11) . Moreover, in several in vivo and in vitro models of CNS injury, IL-10 administration inhibits the morphological alterations associated with glial activation (12Y16), the production of proinflammatory cytokines (13, 17Y22) and enzymes involved in the generation of inflammatory mediators and oxygen-free radicals (23, 24) , leukocyte infiltration (22) , and the production of A chemokines (25) .
In contrast to the adult brain, the immature brain undergoes dramatic physiological and morphological changes over time. In rodents, neuronal and glial differentiation is not achieved in the early postnatal period. Thus, neuronal dendritic arborization is incomplete; axonal growth and myelination progress and neuronal circuits are not well established because synaptic contacts are still being formed (26) . These cytoarchitectural events parallel the development of a functional blood-brain barrier (27) , alterations in extracellular matrix proteins (28) , and the expression and release of numerous growth factors (29) , adhesion molecules (30) , inhibitors of axonal growth (31) , and cytokines (32Y35). All these ongoing processes likely contribute to distinct patterns of response to injury in the immature brain. In this regard, it has been demonstrated that the immature brain displays increased susceptibility to excitotoxicity (36Y39) and to proinflammatory molecules (40, 41) . Moreover, some studies suggest that the inflammatory response associated with injury is exacerbated in the immature brain. For example, leukocyte infiltration and microglial reactivity after a systemic inflammatory challenge are more rapid and higher in 7-day-old postnatal brains than in adult rat brains (42) .
Despite a putative key role that IL-10 and other antiinflammatory molecules may play in the control and termination of the inflammatory response in the immature brain (and consequently in determining lesion outcome), very little is known about expression patterns of IL-10 and its receptor in the normal and injured immature postnatal CNS. To obtain a better understanding of the role played by this cytokine in the injured developing brain, we determined the cellular source and the spatiotemporal expression patterns of IL-10 and its receptor, IL-10RI, after an excitotoxic injury to the postnatal brain.
MATERIALS AND METHODS

Animals and Excitotoxic Lesions
A total of 150 Black-Hooded Long Evans postnatal rats (age, 9 days [P9]; weight, 15Y20 g) of both sexes from 15 litters were used. The litter size was cut down to 10 on P0, and all litters were composed of similar numbers of males and females. Animals were divided into an excitotoxin lesioned experimental group (n = 75) and a nonlesioned control group (n = 75). Excitotoxic lesions were induced as previously described (43, 44) . Briefly, the animals were placed into a stereotaxic frame adapted for newborns (David Kopf Instruments, Tujunga, CA) under isoflurane anesthesia (Veterinaria Esteve, Barcelona, Spain). The skulls were opened using a drill, and 0.15 KL of saline solution (0.9% NaCl, pH 7.4) containing 18.5 nmol N-methyl-D-aspartate (NMDA; Sigma, Steinheim, Germany) was injected into the right sensorimotor cortex at the level of the coronal suture, at 2 mm lateral to bregma and 0.5 mm of depth. After suture, the pups were placed on a thermal pad and maintained at normothermia for 1 hour before being returned to their mother. N-methyl-DaspartateYinjected and nonlesioned control animals were killed at 10 hours postlesion (hpl), 24 hpl, 48 hpl, 72, hpl, and 7 days postlesion (dpl). Experimental animal work in this study was conducted according to Spanish regulations following European Union directives. All experimental procedures were approved by the ethical commission of the Autonomous University of Barcelona. All efforts were made to minimize animal suffering in every step.
RNA Isolation and cDNA Synthesis
For mRNA quantification by quantitative real-time polymerase chain reaction (PCR), 5 lesioned animals and 5 controls were used for each survival time. Animals were killed by decapitation, and brains were immediately removed, frozen in liquid nitrogen, and stored at j80-C. RNA was isolated by using the Total RNA isolation system Kit (Promega, Madison, WI) according to the manufacturer's instructions. Concentration and purity of mRNA were determined by measuring absorbance at 260 and 280 nm and by electrophoresis. To eliminate putative genomic DNA traces, further digestion with turbo-DNase (Applied Biosystems, Foster City, CA) was performed at 37-C for 45 minutes followed by enzyme deactivation at 70-C for 15 minutes. To quantify IL-10RI and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), 2 Kg mRNA was retrotranscribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) with random hexamers (Applied Biosystems) for IL-10 quantification and specific oligonucleotide primers (Table 1) . Retrotranscription was performed at 42-C for 45 minutes, followed by enzyme deactivation at 95-C for 5 minutes and 4-C for 5 minutes.
Quantitative Real-Time PCR
For quantitative real-time PCR, the SYBR Green PCR Core reagents kit was used (Applied Biosystems). Amplification of cDNA was performed in MicroAmp Optical 384-wells Reaction Plates (Applied Biosystems) on an ABI PRISM 7900HT Sequence detection System (Applied Biosystems). To amplify IL-10RI and GAPDH cDNA, the reaction mixture (10 KL) was composed of SYBR Green buffer, 3 mM of MgCl 2 , 875 KM of dNTPs with dUTP, 0.3 U of AmpliTaq Gold, 0.12 U of Amperase UNG, 7.5 pmol of each primer (Table 1) , 12.5 ng of cDNA, and nuclease-free H 2 O. For IL-10 cDNA amplification, the reaction mixture (15 KL) was the same as previously described. In this case, however, 0.75 pmol of each primer (Table 1 ) and 100 ng of cDNA were added. In all cases, reaction conditions were 2 minutes at 50-C and 10 minutes at 95-C followed by 40 cycles of 15 seconds at 95-C and 1 minute at 59-C. The levels of IL-10 and IL-10RI mRNA expression were quantified in relation to the level of the housekeeping gene GAPDH as 2 (Threshold cycle of target mRNA-Threshold cycle of GAPDH mRNA) .
IL-10 Enzyme-Linked Immunosorbent Assay
For protein quantification by enzyme-linked immunosorbent assay (ELISA), 5 lesioned animals and 5 controls were used for each survival time. Animals were killed by decapitation, and brains were immediately removed, frozen in liquid nitrogen, and stored at j80-C. Samples were weighed and homogenized in ice-cold Tris-50 mM/EDTA-1 mM buffer containing a cocktail of protease (Roche, Mannheim, Germany) and phosphatase (Sigma) inhibitors using a potter homogenizer. Interleukin-10 protein concentration was evaluated using the interleukin-10 [(r)IL-10] Rat ELISA Biotrack system (GE Healthcare, Buckinghamshire, UK), according to the manufacturer's instructions. Total protein concentration of each sample was obtained using the bicincholinic acid, method as previously described (45) .
Immunohistochemistry
For histological analysis, 5 lesioned animals and 5 controls were used for each survival time. Animals were perfused intracardially using 4% paraformaldehyde (Sigma) in 0.1 M phosphate buffer (pH 7.4). Subsequently, brains were removed, postfixed for 4 hours in 4% paraformaldehyde, cryoprotected in 30% sucrose, frozen with dry CO 2 , and stored at j80-C. Parallel sections (30 Km thick) were cut in a cryostat (Leica Microsystems, Nussloch, Germany) and stored either mounted on gelatin-coated slides or as freefloating sections in Olmos antifreeze buffer at j20-C.
Cryostat sections mounted on gelatin-coated slides were processed for immunohistochemical detection of IL-10 and IL-10RI. Briefly, endogenous peroxidase was blocked for 10 minutes with 2% H 2 O 2 (Sigma) diluted in 70% methanol (VWR Prolabo, Briare, France) solution. The sections were then treated with buffer blocking containing 10% fetal calf serum (Invitrogen, Paisley, UK), 0.3% bovine serum albumin (Sigma), and 1% Triton X-100 (Sigma) in pH 7.4 Tris-buffered saline at room temperature for 1 hour and incubated at 4-C with either rabbit antiYIL-10 (Serotec, Oxford, UK) (24-hour incubation) or rabbit antiYIL-10RI (Santa Cruz, Heidelberg, Germany) (48-hour incubation); the primary antibodies were diluted 1:400 and 1:100, respectively, in buffer blocking. After washing in Tris-buffered saline, the sections were incubated at room temperature for 1 hour with anti-rabbit biotinylated secondary antibody (GE Healthcare) diluted 1:200. Finally, tissue was incubated with streptavidin peroxidase (Vector Laboratories, Burlingame, CA) diluted to 1:400. The peroxidase reaction product was visualized by incubating sections in 100 mL of Tris buffer containing 50 mg 3 ¶3-diaminobenzidine (Sigma) and 33 KL H 2 O 2 (Sigma). Finally, sections were dehydrated, cleared in xylene (Panreac, Barcelona, Spain), and coverslipped in DPX (Panreac). antibodies and subsequently with Cy2-conjugated streptavidin (GE Healthcare) at 1:1000. Sections were further processed by using the following primary antibodies produced in mouse: NeuN (Chemicon, Temecula, CA), GFAP (Dako, Glostrup, Denmark), adenomatous polyposis coli (Calbiochem, Darmstadt, Germany), or ED-2 (Serotec) at 1:700, 1:1000, 1:400 and 1:500, respectively. In all cases, Cy3-conjugated anti-mouse (GE Healthcare) secondary antibody was used at 1:1000. Sections processed for double labeling with TL were first processed for IL-10 or IL-10RI visualization as described above but using Cy2-conjugated anti-rabbit secondary antibody (GE Healthcare) at 1:500. Sections were then incubated with biotinylated TL obtained from Lycopersicon esculentum at 1:150 and visualized with Cy3-conjugated streptavidin (GE Healthcare) at 1:1000.
Double-Labeling Immunohistochemistry
Double-Labeling Evaluation
Double-labeled sections were analyzed using a Nikon Eclipse E600 (Nikon, Badhoevedorp, The Netherlands) and a Leica-TSC-SP2 confocal microscope (Leica). Qualitative observations regarding changes in the density of double-labeled cells and intensity of labeling were evaluated at 40Â at all different survival times and areas, including the cerebral cortex, hippocampus, striatum, and corpus callosum, both in NMDA-lesioned animals and nonlesioned controls.
Densitometry Quantification and Statistical Analysis
For the densitometry study, 6 sections/animal separated by 300 Km (from +0.9 to j0.6 mm in relation to bregma) from all animals processed for IL-10 or IL-10RI single immunohistochemistry were used. One image per section ( Fig. 1 ) was taken using a 20Â objective from the cortex of each lesioned animal and from the corresponding cortex of each nonlesioned control animal. Densitometry analysis was performed using analySIS 3.2 software (Soft Imaging System, Munster, Germany).
Statistical analysis was performed using Statview 5.0.1 software. Differences between groups were evaluated by means of one-way analysis of variance followed by Fisher post hoc test. All values are presented as mean values T SEM, and p G 0.05 was considered statistically significant.
RESULTS
N-methyl-D-aspartate injection into the sensorimotor cortex of the P9 immature rat brain induced a well-characterized excitotoxic lesion involving neuronal degeneration and glial response that involved different areas such as the sensorimotor cortex, corpus callosum, striatum, and hippocampus, as previously described (46Y48). control brains; no changes were observed at the other survival times (Fig. 2) . Accordingly, the amounts of IL-10 protein in lesioned brains as determined by ELISA were significantly increased at 72 hpl and remained elevated at 7 dpl compared with levels observed at earlier time points (Fig. 3) . Interleukin-10 proteins levels were always higher in lesioned animals than in nonlesioned controls at the different survival times analyzed (Fig. 3) . These observations were corroborated by densitometry analysis of sections stained by immunohistochemistry (Fig. 4) .
By immunohistochemistry, IL-10 was mainly found in white matter tracts (e.g. the forceps minor, corpus callosum, external capsule, and the cingulum, which was the most intensely stained area) in nonlesioned control brains of all ages (Fig. 5A ). There were no differences in IL-10 expression between nonlesioned control brains and the contralateral hemispheres of NMDA-injected animals. As determined by their morphological features and by double immunolabeling, IL-10+ cells in nonlesioned control brains were identified as astrocytes (Fig. 5B) . Most IL-10+ cells were present in white matter tracts, but in the gray matter, IL-10 was often found in blood vessel walls (Figs. 5C, D) , in GFAP+ layer 1 astrocytes (Figs. 5E, F), and in GFAP + periventricular astrocytes mainly adjacent to the lateral ventricles (not shown).
At 10 hpl, excitotoxin lesioned brains displayed increased IL-10 immunoreactivity in astroglial cells in the cingulum (Figs. 6A, B) and corpus callosum. Increased IL-10 immunoreactivity was also found in blood vessels (Figs. 6C, D) in gray matter areas of the lesioned cortex, hippocampus, . At 72 HPL, it was maximal and remained significantly increased over controls at 7 days postlesion (DPL) ( # p G 0.05). No significant differences were found at 7 DPL between lesioned and control brains due to the fact that IL-10 levels observed in control brains at this time point are significantly higher than those observed at early survival times ( and striatum. At 24 hpl (Fig. 7B) , few faint IL-10+ astrocytes (Figs. 6E, F) were observed in the periphery of the injured cortex, striatum, and hippocampus, whereas at 48 hpl (Fig. 7C) , the number of IL-10+ astrocytes and their immunostaining intensity in the lesioned areas were increased. At this time point, some IL-10+ microglia/macrophages were also found in centers of the cortical lesions. By 72 hpl (Fig. 7C) , the number and the IL-10 immunolabeling intensity of IL-10+ microglia/macrophages and IL-10+ astrocytes reached maximum levels (Figs. 6GYI) , whereas, at 7 dpl (Fig. 7D) , IL-10 was still present in astrocytes forming the glial scar throughout the whole cortical (Figs. 6J, K) , striatal, and hippocampal lesioned areas. Interleukin-10 was never observed in oligodendrocytes (Fig. 6L), neurons (Fig. 6M) , or perivascular cells (not shown).
IL-10RI Gene and Protein Expression in Control and Excitotoxin Injured Postnatal Rat Brain
Interleukin-10 receptor I gene expression in lesioned brains was significantly increased at 48 hpl in comparison to that in nonlesioned controls (Fig. 8) . This result correlated with densitometry analysis of immunostained sections; both showed that total IL-10RI immunostaining intensity was significantly increased at 48 hpl (Figs. 9AYF) . Interleukin-10 receptor I immunostaining intensity in lesioned brains was significantly higher compared with that in control animals at all the evaluated survival times except for 7 dpl (Figs. 9AYF) .
Microscopic analysis revealed that in nonlesioned control brains of all ages, IL-10RI immunoreactivity was found in white matter tracts, mainly in the cingulum, in association with blood vessels (Figs. 5G, H) and in cells displaying a glial morphology (Fig. 5I) . No differences in IL-10RI expression between the nonlesioned control brains and the contralateral side of NMDA-injected brains were found at any survival time. As analyzed by double immunohistochemistry, IL-10RI+ cells were identified as endothelial (Fig. 5H) , oligodendroglial (Fig. 5J), microglial (Fig. 5K) , and astroglial ( Fig. 5L ) cells but not neurons.
In lesioned brains, at 10 hpl, strong IL-10RI immunoreactivity was observed in the injured cingulum (Fig. 10A ) and corpus callosum, whereas faint immunoreactivity was found in the injured gray matter in the cortex, striatum, and hippocampus. At this survival time, cells expressing IL-10RI were identified as astrocytes (Fig. 10B) , microglia/macrophages (Fig. 10C), oligodendrocytes (Fig. 10D) , and endothelial cells. At 24 hpl (Fig. 11B) , in the lesioned cortex, striatum, and hippocampus, some IL-10RI+ cells displaying a glial-like morphology were seen (Fig. 10E ) and identified as microglia/ macrophages (Fig. 10F) and astrocytes (Fig. 10G) . Interleukin-10 receptor I+/TL+ cells had small and rounded morphologic appearances. At 48 hpl (Fig. 11C) , when IL-10RI immunoreactivity reached the maximum level (Fig. 10H) , an elevated number of IL-10RI+ microglia/macrophages (Fig. 10I) and astrocytes (Fig. 10J) were found in the lesioned gray matter of the cortex, striatum, and hippocampus. At 72 hpl (Fig. 11C) , IL-10RI immunoreactivity started to decrease (Fig. 10K) , although some IL-10RI+ astrocytes (Fig. 10L ) and microglia/ macrophages (Fig. 10M ) remained in the injured areas. At 7dpl (Fig. 11D) , no IL-10RI immunoreactivity was observed in the lesioned cortex (Fig. 10N) , striatum, and hippocampus, whereas the cingulum and corpus callosum showed the same basal immunoreactivity pattern observed in the nonlesioned showed that in comparison, IL-10 immunostaining intensity was significantly greater than in controls in lesioned brains at all evaluated survival times (*p G 0.05); this was even the case at 7 days postlesion (dpl) when the levels observed in control animals were significantly higher than those observed at other time points ( & p G 0.05). Moreover, IL-10 immunostaining intensity reached the maximum levels at 72 hours postlesion (hpl) ( # p G 0.05) (A, E) and remained significantly elevated at 7 dpl ( # p G 0.05) (A, F) compared with those detected at 10, 24, and 48 hpl (AYD). Data are presented as mean T SEM of relative gray units of the whole image minus the relative gray units of the background labeling. Scale bars = 20 Km.
brain. Interleukin-10 receptor I was never observed in neurons (Fig. 10O ).
DISCUSSION
This study shows that the anti-inflammatory cytokine IL-10 and its receptor (IL-10RI) are present in the normal immature brain, suggesting a possible anti-inflammatory role in the intact immature brain. Moreover, both IL-10 and IL-10RI are upregulated, mainly in glial cells, after acute excitotoxic damage, suggesting that their expression may play a key role regulating the final lesion outcome. A, B) . Interleukin-10 was also observed in association with tomato lectin (TL)+ blood vessel walls in gray matter areas such as the cortex (CX) (C, D) and in layer 1 astrocytes (E, F). Interleukin-10 receptor I immunoreactivity was observed in endothelial cells (G, H) and adenomatous polyposis coli (APC)+ oligodendrocytes (I, J) in white matter tracts such as the corpus callosum (CC), and in TL+ microglia/macrophages (I, K) and GFAP+ astrocytes (L) mainly in the CG. The panels are from nonlesioned controls corresponding to 72 hours postlesion (hpl). Scale bars = 20 Km.
IL-10 and IL-10RI Are Expressed in the Normal Immature Rat Brain
Previous in vivo studies have reported the presence of IL-10 and IL-10RI in the normal adult human brain (5, 49Y51). Specifically, IL-10 has been shown in white matter astrocytes (5, 49) , and IL-10RI expression has been reported in astrocytes, oligodendrocytes, and microglial cells of white matter tracts (5, 50, 51) . Although it has been recently reported that IL-10 expression can be detected in the immature rat brain (33) , neither the cellular source of IL-10 nor the pattern of IL-10RI expression in the neonatal brain has been determined. We report that the cellular expression A, B) . In lesioned gray matter areas such as the cortex (CX), IL-10 immunoreactivity was found in tomato lectin (TL)+ blood vessel walls (C, D). A few faint staining IL-10+/GFAP+ astrocytes were observed in the periphery of the lesioned cortex at 24 hpl (E, F). Increased GFAP+ astroglial IL-10 immunoreactivity was observed at 72 hpl in the same area (G, H). At the same time point, IL-10+/TL+ microglia/macrophages were found in the lesion core (G, I). At 7 days postlesion (dpl), IL-10+/GFAP+ astrocytes were observed throughout the whole lesioned area (J, K). Interleukin-10 was never observed in adenomatous polyposis coli (APC)+ oligodendrocytes (L) or in NeuN+ neurons (M). Scale bars = 20 Km. patterns of IL-10 and IL-10RI in the immature brain coincide with those reported in the adult, although we also found IL-10 in periventricular and layer 1 astrocytes and IL-10 and IL-10RI in blood vessel walls. In vitro studies have similarly shown that under basal conditions in culture, microglial, astroglial, and endothelial cells can produce IL-10 (52Y54); IL-10RI is expressed in astrocytes, oligodendrocytes, microglia, and endothelial cells (23, 53, 55) . The expression of IL-10RI in glial and endothelial cells in the normal immature CNS suggests that IL-10 could exert its effects on these cell populations. In this regard, many in vivo and in vitro studies have analyzed the effects of this cytokine on glial and endothelial cells (12, 14Y21, 23Y25, 56Y59). Most of these studies were, however, performed with activated cells and not under basal conditions. In the postnatal period, glial cells in white matter tracts in which we observe IL-10 and IL-10RI expression are still immature and, in the case of astrocytes and microglia, show an activated phenotype (60) . In immature white matter, microglia exhibit an amoeboid morphology (61, 62) and express immune-related molecules (e.g. major histocompatibility complex type I) (47, 63) , whereas astrocytes show a hypertrophic phenotype, elevated GFAP content (48) , and the capacity to produce inflammation-related molecules such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) (64). The activated phenotype of glial cells in postnatal white matter tracts is probably a consequence of important ongoing developmental processes, including myelination, remodeling, and establishment of adult connections (26) . Therefore, together with the well-known anti-inflammatory role of IL-10, our present observations suggest that IL-10 and IL-10RI expression in the postnatal white matter may control the intrinsic inflammatory environment and protect highly susceptible cell types such as oligodendrocyte progenitors (41) .
We also found IL-10 expression to be proximal to points of entrance of microglial precursors to the brain parenchyma, including the meninges, blood vessels, and ventricle walls (61, 62) . From the last days of embryonic life to the third postnatal week, microglial precursors infiltrate the nervous parenchyma where they migrate, proliferate, and differentiate from primitive ameboid to ramified resting microglia (61, 62) . Although the mechanisms that control this process are still unknown, it has been widely reported that IL-10 is implicated in the modulation of molecules involved in leukocyte infiltration to the damaged brain parenchyma, such as adhesion molecules (56, 59 ) and chemokines (57, 58, 65) , suggesting a putative role of this cytokine in controlling the entry of microglial precursors to the immature brain.
Furthermore, the specific anatomic localizations of the expression of anti-inflammatory IL-10 and its receptor in the normal brain suggest that they are expressed in areas that are highly susceptible to suffer an inflammatory response. Specifically, they are observed in areas neighboring the Boutside[ of the brain (i.e. meninges, blood brain barrier and ventricle walls), where several inflammatory-related molecules such as antioxidant enzymes as Cu/Zn superoxide dismutase are also expressed (66) .
IL-10 and IL-10RI Gene and Protein Expression Are Upregulated After an Excitotoxic Injury to the Immature Rat Brain
Although IL-10 expression is upregulated after several types of insults in the adult CNS (5Y10, 67), a recent study showed that IL-10 mRNA was downregulated at 1 hpl, 3 hpl, and 14 dpl in P7 rats after brain hypoxia/ischemia (68); no differences were observed at 24 hpl and no intermediate survival times were analyzed. Therefore, ours is the first report to show that in the developing brain, there is upregulation of IL-10 and IL-10RI gene and protein expression at 72 and 48 hpl, respectively, after excitotoxic injury. The delay observed between the peaks of expression of IL-10 and IL-10RI might be explained by the fact that IL-10 can downregulate the expression of its own receptor (53) . It is noteworthy that IL-10 and IL-10RI protein increases were found from the earliest survival time studied, when no variations in the amount of IL-10 and IL-10RI mRNA were observed. One possible explanation of this observation could be the existence of posttranscriptional regulatory mechanisms; more experiments are needed to better understand the processes regulating IL-10 expression.
To our knowledge, the cellular sources of IL-10 and IL-10RI after CNS injury have only been studied in adult MS patients and in experimental autoimmune encephalomyelitis; IL-10 was mainly observed in astrocytes but also in microglial cells, and IL-10RI was mainly found in microglia/macrophages but also in oligodendrocytes (5Y7, 50). We show here that IL-10 is expressed by astroglial, microglial, and endothelial cells and that IL-10RI is found in astroglial, microglial, oligodendroglial, and endothelial cells in the excitotoxininjured postnatal rat brain. These findings are in agreement with in vitro observations in which there was upregulation of both molecules in stimulated astroglial, microglial, and endothelial cells (20, 52Y54, 69Y71) and that oligodendroglial cells in culture were able to express IL-10RI but not IL-10 after lipopolysaccharide (LPS) administration, (23) .
Because IL-10RI is expressed in glial and endothelial cells in CNS injury, many in vivo and in vitro studies have intended to determine the functional effects of IL-10 administration on these cell types. In ischemia, spinal cord trauma, and corticectomy, IL-10 can inhibit the morphological changes that are characteristic of the microglial and astroglial response (12Y16), and IL-10 can reduce the production of proinflammatory cytokines as TNF, IL-1A, and IL-6 in activated microglial and astroglial cells in vitro (17Y21). Furthermore, IL-10 modulates the astroglial production of A-chemokines (25) and microglial, astroglial, and oligodendroglial production of inducible nitric oxide synthase (19, 20, 23) and cyclooxygenase-2 (24) . Previous studies have also reported the inhibitory role of IL-10 over the production of endothelial cell molecules that are implicated in leukocyte infiltration (i.e. intercellular cell adhesion molecule and vascular cell adhesion molecule) (56, 59 ) and other chemokines (i.e. IL-8 and monocyte chemoattractant protein-1) (57, 58, 65) . . At 24 hpl, at the lesioned gray matter areas such as the cortex (CX), there were a few faint staining IL-10RI+ microglia/macrophages (E, F) and astrocytes (E, G). At 48 hpl, when IL-10RI immunoreactivity was maximal (H), there was an increase of IL-10RI+ astrocytes (J) and microglia/macrophages (I) in the injured gray. At 72 hpl, when IL-10RI immunoreactivity started to decrease (K), some IL-10RI+ astrocytes (L) and microglia/ macrophages (M) were still observed at the damaged gray matter, whereas at 7 days postlesion (dpl), no IL-10RI immunoreactivity was observed in these areas (N). Interleukin-10 receptor I was never found in neurons (O). Scale bars = 20 Km.
Anti-Inflammatory Role of IL-10 in the Immature Brain
The upregulation of IL-10 and IL-10RI after immature brain damage becomes particularly important in responses to CNS damage during the neonatal period that differ from those in adults (36, 39, 72, 73) . These differences include increased susceptibility to excitotoxic damage (74) and inflammatory molecules, as suggested by the linkage between elevated levels of proinflammatory cytokines during the prenatal period and the development of periventricular leukomalacia (40, 41) and exacerbated response to an inflammatory challenge induced by LPS administration (42) . Moreover, in an in vitro model of microglial maturation, Chock and Giffard (75) found that either glucose or oxygen-glucose deprivation of Byounger[ microglial cells induced a greater production of TNF compared with Bolder[ microglial cells. In this regard, after LPS-mediated activation, blood-derived cells from term and preterm infants display an increased production of IL-6 and IL-8 (76) and reduced production of anti-inflammatory molecules such as IL-10 and transforming growth factor beta; they also show a reduced inhibitory capacity for the production of the proinflammatory molecules IL-1A, IL-6, IL-8, and TNF (77) . Finally, it has been also demonstrated that neonatal T cells are less capable of producing IL-10 after stimulation than adult T cells (78, 79) .
Because the inflammatory response seems to be exacerbated during immaturity and because activated neonatal blood cells display an inability to upregulate and respond to anti-inflammatory molecules such as IL-10, whether the postnatal brain is able to upregulate and to respond to IL-10 after an injury is an important question. In this context, Mesples and colleagues (16) reported that intracerebroventricular IL-10 administration did not modulate lesion outcome in a model of acute postnatal brain injury; this is in contrast to what has been observed in the adult brain (80) . In addition, in the same experimental model, lesion outcome did not differ in IL-10 knockout mice; this strongly suggests that the damaged postnatal brain exhibits a deficient response to IL-10 (16). We show here, however, that IL-10 and IL-10RI gene and protein expression are upregulated after an acute injury to the postnatal rat brain, thereby discarding the possibility that the damaged postnatal brain is unable to increase the production of IL-10 and its receptor. In this context, it has been reported that systemic IL-10 administration can inhibit astroglial and microglial reactivity in a neonatal model of maternal infection-mediated white matter damage (14) and the microglial response in a neonatal model of ibotenate-mediated white matter damage (16) , suggesting that neonatal glial cells can respond to IL-10 in specific conditions.
Finally, previous results obtained by our group in the same excitatory injury paradigm used in the present study showed that an increase in the expression of proinflammatory cytokines (64) and enzymes implicated in the production of oxygen free radicals (81) occurs before upregulation of IL-10 and IL-10RI and that their expression started to decrease at the time points that expression of IL-10 and its receptor are upregulated. This temporal correlation suggests that IL-10 also has an anti-inflammatory role in the immature brain. More experiments are needed for a better understanding about the regulation of the inflammatory response associated with CNS injury during developmental periods. 
